/Companies

Vitruvias Therapeutics

Auburn, US · Founded 2013 · Delaware corporation

Find your way into Vitruvias Therapeutics

Sign up to see every warm intro you have to Vitruvias Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Vitruvias Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Vitruvias Therapeutics was a pharmaceutical company; it has ceased operations, and its products are now owned and/or distributed by H2-Pharma LLC.

Founders & leadership

BM
Bryce M HarveyExecutiveBryce M Harvey has over 30 years of pharmaceutical industry experience spanning retail sales, drug wholesaling, and major pharmaceutical companies, including 22 years with Johnson and Johnson. He founded and led Midlothian Laboratories as president from 2003 to 2012, established H2 Pharma in 2014, and was co-founder of Vitruvias Therapeutics.
RDRoger D Graben
Roger D GrabenVice President, Commercial Operations & Quality Assurance2016–2018Executive officer at Vitruvias Therapeutics, a pharmaceutical company now defunct; holds a Ph.D. in pharmaceutics and is a registered pharmacist with experience across corporate management, operations, business development, supply chain, quality management, pharmaceutical manufacturing, and dosage form development.
CLCarl L Whatley
Carl L WhatleyExecutiveCarl L Whatley was an Executive Officer and Director at Vitruvias Therapeutics, a pharmaceutical company that developed generic products.
CL
Carl Leo Whatley, Jr.General Manager

Board

JW
Jason WildBoard director
MA
Michael AltmanBoard director
ES
Edward SchutterBoard director

Reported raises · per SEC filings

Form D private placements

$11.7M disclosed across 2 rounds · 2014–2017

▶$11.5MraisedJan 2018 · 23 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Bryce M HarveyExecutive Officer, Director
  • Jason WildDirector
  • Roger D GrabenExecutive Officer
  • Michael AltmanDirector
  • Edward SchutterDirector
  • Carl L WhatleyExecutive Officer, Director
Offering amount
$11.5M
Amount sold
$11.5M
Minimum investment
$25K
Proceeds to insiders
$1.5M
First sale
Dec 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$200KraisedJul 2014 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Carl Leo Whatley, Jr.Executive Officer
  • Bryce M HarveyExecutive Officer
Offering amount
$2.5M
Amount sold
$200K
Minimum investment
$25K
Proceeds to insiders
$595K
First sale
Jul 2014
Incorporated
Limited Liability Company, Delaware, 2013
Federal exemptions
05, 06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

Companies working in the same space as Vitruvias Therapeutics.

In the news

Frequently asked questions

What does Vitruvias Therapeutics do?
Vitruvias Therapeutics was a pharmaceutical company; it has ceased operations, and its products are now owned and/or distributed by H2-Pharma LLC.
How much funding has Vitruvias Therapeutics raised?
Vitruvias Therapeutics has disclosed $11.7M raised across 2 rounds.
Where is Vitruvias Therapeutics headquartered?
Vitruvias Therapeutics is headquartered in Auburn, US.